Scientists at Lausanne University Hospital (CHUV) and EPFL have discovered a highly potent monoclonal antibody that targets the SARS-CoV-2 spike protein and is effective at neutralizing all variants of concern identified to date, including the delta variant.
Their findings are published in the prestigious journal Cell Reports.
The newly identified antibody was isolated using lymphocytes from COVID-19 patients enrolled in the ImmunoCoV study being carried out by CHUV’s Service of Immunology and Allergy. This antibody is one of the most powerful identified so far against SARS-CoV-2. Structural characterization of the antibody indicates that it binds to an area that is not subjected to mutations of the spike protein. Through this tight interaction, the antibody blocks the spike protein from binding to cells expressing the ACE2 receptor, which is the receptor the virus uses to enter and infect lung cells. That means the antibody halts the viral replication process, enabling a patient’s immune system to eliminate SARS-CoV-2 from the body. This protective mechanism was proven through in vivo tests on hamsters; specimens that were administered the antibody were protected against infection even after receiving a highly infectious dose.
In addition to its antiviral properties, the new antibody is designed to have a lasting effect in humans. A typical unaltered antibody provides protection for up to 3–4 weeks. But this new one can protect patients for 4–6 months. That makes it an interesting preventive-treatment option for unvaccinated at-risk individuals or for vaccinated individuals who are unable to produce an immune response. Immunocompromised patients, organ transplant recipients and those suffering from certain kinds of cancer could be protected against SARS-CoV-2 by receiving antibody injections two or three times a year.
CHUV and EPFL now plan to build on these promising results in association with a start-up company which will perform clinical development and production of the antibody-containing drug, through cooperation and intellectual property agreements. Clinical trials of the drug should begin in late 2022.
Treatment or prophylaxy
This research was conducted jointly by CHUV’s Service of Immunology and Allergy, headed by Prof. Giuseppe Pantaleo and Dr. Craig Fenwick, and by EPFL’s Laboratory of Virology and Genetics, headed by Prof. Didier Trono and Dr. Priscilla Turelli. The research team was able to respond to the pandemic and discover this neutralizing antibody so quickly thanks to the multi-year support of the Swiss Vaccine Research Institute. Prof. Pantaleo’s department at CHUV also received support from the Corona Accelerated R&D in Europe (CARE) program, which is part of the Innovative Medicine Initiative (IMI) – a public-private partnership that seeks to address bottlenecks in the drug discovery and development process in Europe.
The discovery of this new antibody marks a major step forward in the fight against COVID-19. It opens the door to improved treatments for severe forms of the disease and to enhanced prophylactic measures, especially for patients with weakened immune systems. However, this antibody is not intended to replace COVID-19 vaccines, which remain the most effective way to prevent infection.
Original Article: Scientists discover a highly potent antibody against SARS-CoV-2
The Latest on: SARS-CoV-2 monoclonal antibody
- Plug-and-play test for keeping track of immunity to Sars-CoV-2 variantson July 1, 2022 at 8:20 am
Many antibody tests have been developed since the pandemic started, but very few are designed to specifically detect the Sars-CoV-2 neutralizing antibodies which prevent infection. Based on protein ...
- New project offers efficient approach when tracking SARS-CoV-2 variantson June 29, 2022 at 10:18 am
An interdisciplinary research team has developed a fast, cost-effective method to detect the circulation of SARS-CoV-2 variants. SARS-CoV-2 is the virus that causes COVID-19. The team, funded by the ...
- Potent antibody with a novel neutralization mechanism against SARS-CoV-2 variantson June 28, 2022 at 7:08 pm
In a recent study posted to the bioRxiv* pre-print server, researchers in the United States described a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal antibody ...
- Cell-based assay highlights differences in antibody neutralizing capacity for SARS-CoV-2 variantson June 27, 2022 at 10:21 pm
A recent study by scientists at Celentyx Ltd, the University of Birmingham, and the University of Warwick and posted to the bioRxiv* preprint server illustrated a cell-based severe acute respiratory ...
- What to Know About Monoclonal Antibodies as COVID-19 Treatmentson June 27, 2022 at 1:11 am
Here’s what we know about how well the monoclonal antibodies are working, and who might benefit from them. When the SARS-CoV-2 virus enters the body, it breaks into the cells and uses them to ...
- What to Know About Monoclonal Antibodies as COVID-19 Treatmentson June 23, 2022 at 6:34 am
COVID-19 is once again surging throughout the U.S., but deaths from the disease don’t seem to be following suit. That’s partly because many people have some level of immunity from vaccination or ...
- Pictor Receives CE Mark for its PictArray™ SARS-CoV-2 Antibody Test, Indicating Whether Patients Require COVID-19 Boosteron June 22, 2022 at 6:03 am
Following a recent funding round raising $6.1 million (NZD $8.8 million), biotech company Pictor today announced it has received confirmation of CE registration for its PictArray™ SARS-CoV-2 IgG ...
- New SARS-CoV-2 antibody cocktailon June 20, 2022 at 10:44 am
Aseem Healthcare (global healthcare company), and Trident Biopharm Solutions (life science consultancy agency) are pleased to announce the development of a new antibody cocktail effective against ...
via Bing News
The Latest on: SARS-CoV-2 monoclonal antibody
via Google News